Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)929.91K
Market Cap
$3.13B
Enterprise Value$704.92M
Total Cash (Recent Filing)$177.88M
Total Debt (Recent Filing)$65.13M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 08, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding94,676,765
10 Day Avg. Volume1,134,659
30 Day Avg. Volume929,910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1837.68
Price to Cash Flow (P/CF)-15.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$52.33Price Target Upside58.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Scholar Rock Holding News
PremiumCompany Announcements
Scholar Rock Holding Appoints Interim Financial Officer
PremiumCompany Announcements
Scholar Rock’s Earnings Call Highlights SMA Progress and Obesity Challenges
PremiumCompany Announcements
Scholar Rock Reports 2024 Financial Results and Progress
---
Bulls Say, Bears Say
Bulls Say
Market PotentialSMA is a sizable $4-5B established commercial market where SRRK could capture at least $1-2B.
Regulatory MilestonesThe FDA has granted apitegromab Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
Research And DevelopmentScholar Rock's research platform could enable selective targeting of TGF-β proteins, with apitegromab potentially being the first effective and safe myostatin inhibitor.
Bears Say
Competition And Market PositionStock is $4B and inexpensive given SMA is a ~$4B established commercial market and SRRK looks best positioned for at least $1-2B peak after BHVN failed.
Market Interpretation RisksThere may be headline risk on how investors would interpret the data and the % or kg reduction of lean muscle loss.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $3.13B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Feb 27, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.601 by -$0.019.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.66.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 94,676,765 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.601. Following the earnings report the stock price went down -2.863%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
---
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.33 (58.34% Upside)
$52.33 (58.34% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.15%
12-Months-Change
Fundamentals
Return on Equity
-82.95%
Trailing 12-Months
Asset Growth
52.69%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
---
SRRK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Scholar Rock, with significant progress in its SMA program and commercial preparations for apitegromab. However, there are challenges and uncertainties in the obesity program related to regulatory expectations and the competitive landscape.Read More>---
SRRK Stock 12 Month Forecast
Average Price Target
$52.33
▲(58.34% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Best Analysts Covering SRRK
1 Year
1 Year Success Rate
13/17 ratings generated profit
1 Year Average Return
+78.97%
reiterated a buy rating 25 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +78.97% per trade.
---